UnknownPhase 2

Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma

Mexico31 participantsStarted 2006-09

Plain-language summary

Liposomal doxorubicin consists on doxorubicin encapsulated in liposomes that are composed of phosphatidylcholine and cholesterol. Liposomal doxorubicin can extravasate into tumors with abnormal vascular endothelium but may not penetrate normal tissues lowering its toxicity and increasing its efficiency. Combining Liposomal doxorubicin with cisplatin could be an effective new chemotherapy treatment for malignant pleural mesothelioma . Hypothesis: Liposomal doxorubicin combined with cisplatin could increase response rates to chemotherapy, progression free survival and overall survival in patients with malignant pleural mesothelioma.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias * ECOG functional status 0 or 2 * No renal function alteration (GFR \>50%) * No hepatic function alteration * Leucocytes more than 2,000/mcl * Hemoglobin more than 10mg/dL * Platelets more than 100,000/mcl Exclusion Criteria: * Patients who had received previous chemotherapy for MPM * Patients who do not accept the treatment

What they're measuring

Progression free survival

Timeframe: 12 months

Over-all survival

Timeframe: 12 months

Trial details

NCT IDNCT00886028

SponsorNational Institute of Cancerología

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2009-04

View on ClinicalTrials.gov More Malignant Pleural Mesothelioma trials